Clinical Trials Logo

Recurrence Tumor clinical trials

View clinical trials related to Recurrence Tumor.

Filter by:

NCT ID: NCT04656769 Completed - Analgesia Clinical Trials

Analgesia aNd caNcer recUrrence Lung cAncer Resection

Start date: December 17, 2018
Phase:
Study type: Observational

The choice of analgesia after cancer surgery may play a role in the onset of recurrence, particularly opioids seem to play a role in the immune system by promoting cancer cell proliferation and migration. Based on this consideration, our aim was to assess the impact of perioperative analgesia's choice on cancer recurrence after curative surgery for Stage I Non-Small Cell Lung Cancer. The investigators retrospectively reviewed the records of patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012. Patients received analgesia either by peridural (PERI group) or, in case of patient refusal or failure in catheter positioning, intravenous analgesia with opioids (EV group). Follow-up was concluded in August 2019. The five-year cumulative incidence of recurrence and the overall survival were evaluated and adjusted with a propensity score matching methodology.

NCT ID: NCT04640363 Recruiting - HCC Clinical Trials

Combi-elastography Assessment of HCC Recurrence After Thermal Ablation Multi-center Study

Start date: December 1, 2020
Phase:
Study type: Observational

Combined F index, A index,ATT index and spleen stiffness to predict tumor recurrence in different liver settings after thermal ablation of HCC.

NCT ID: NCT04499833 Recruiting - Recurrence Tumor Clinical Trials

HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma

HepatoPredict
Start date: March 25, 2021
Phase: N/A
Study type: Interventional

Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing clinical morphological models used in most centres (Milan Criteria), can exclude potential candidates and include patients with aggressive biological behaviour. To more accurately select candidates for liver transplant, the inclusion of criteria that could predict the behaviour and aggressiveness of tumours, such as molecular markers, might be useful. The investigators propose the use of a new algorithm (HepatoPredict Prognostic Tool), that combine clinical and molecular criteria that address the biology of tumours, in a single centre prospective, intervention study. Data from the "HepatoPredict genomic signature" are added to the clinical and imagiology algorithm. Based on this tool, patients outside the usual eligibility criteria for liver transplant will be proposed for this treatment. These patients will be transplanted with marginal livers or with livers from patients with Familial Amyloid Polyneuropathy, not competing with patients on the waiting list. Patients will be followed up to 60 months after transplant, to assess survival and HCC recurrence with biannual imagiology screening. Survival and disease-free-survival rates will be compared with those obtained by the usual management of patients included and excluded by Milan Criteria.

NCT ID: NCT04136522 Recruiting - Recurrence Tumor Clinical Trials

Usefulness of the Artery First Approach in Pancreatic Cancer Surgery

Start date: January 10, 2020
Phase: N/A
Study type: Interventional

This study is aimed to evaluate difference of the 2 year recurrence free survival after pancreaticoduodenectomy for pancreatic cancer between artery-first approach and conventional procedure groups.

NCT ID: NCT04129606 Active, not recruiting - Bladder Cancer Clinical Trials

Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy

TURBT-BP
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

In view of sparse data of precise definition, risk factors, natural history and management of bladder perforation following Transurethral resection of bladder tumour (TURBT). We aim to correlate the relation between the site, depth and extent of resection with bladder perforation. Also, correlation between vertical depth, horizontal extent of resection and recurrence and progression of tumor

NCT ID: NCT04053231 Not yet recruiting - Surgery Clinical Trials

Hepatocarcinoma Recurrence on the Liver Study - Part2

HERCOLES2
Start date: September 2019
Phase:
Study type: Observational [Patient Registry]

Rationale for the trial. To evaluate the impact of surgery on hepatocarcinoma recurrence. Thus, to evaluate the impact of different clinical, radiological, histopathological variables on recurrence after surgical treatment. The nature of this study will allow to observe, over time, the distribution of the considered collection variables, allowing a strictly observational monitoring of possible associations able to suggest models or interpretations, which can then be the basis for the construction of prospective and randomized studies.

NCT ID: NCT03658785 Recruiting - Solid Tumor Clinical Trials

Immunotherapy for the Treatment of Advanced Solid Tumor

Start date: April 28, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes (TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and advanced solid tumors.

NCT ID: NCT03547388 Completed - Clinical trials for Head and Neck Neoplasms

Moderate Whole Body Hyperthermia for Patients Undergoing Re-irradiation for Head and Neck Cancer -Influence on the Tumor Microenvironment

GKH-TMM
Start date: July 1, 2018
Phase: Phase 1
Study type: Interventional

The aim of the study is to determine the feasibility and efficacy of moderate weekly whole Body hyperthermia Treatment during radiochemotherapy for pre-irradiated locally or regionally recurrent head and neck squamous cell carcinomas. The Primary aim of the study is feasibility, defined as 80% of patients completing at least four applications of hyperthermia. Secondary endpoints include an increase of Tumor Perfusion by the use of hyperthermia, measured by magnetic resonance Imaging during week two of Treatment and reduction of Tumor hypoxia, measured by hypoxia specific Positron emission tomography.

NCT ID: NCT03457389 Recruiting - Pituitary Adenoma Clinical Trials

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Start date: February 22, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether inhibition of serum prolactin levels below normal range during cabergoline administration may reduce the recurrence rate after drug withdrawal in patients with prolactinomas.

NCT ID: NCT03423992 Recruiting - Glioma Clinical Trials

Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Start date: March 2, 2018
Phase: Phase 1
Study type: Interventional

A pilot study to determine the safety and efficacy of chimeric antigen receptor T cell (autologous T cells transduced with a lentiviral vector expressing chimeric antigen receptor with or without anti-PDL1 antibody) personalized immunotherapy for patients with recurrent malignant gliomas based on the expression of tumor specific/associated antigens (EGFRVIII, IL13Rα2, Her-2, EphA2, CD133, GD2).